RIGEL - Oral RA Market - Room for Syk Also
2013 will be a crucial year for RIGL, as it is highly dependant on the success of fostamatinib’s (FosD, formerly R788, PhIII, RA, partnered with AstraZeneca) clinical data from its pivotal PhIII trials OSKIRA-I, II, and III are expected to be out in YE12/1H13. Based on our analysis of the potential of Syk target in RA (analysis done by prototyping system for inflammation biology) and validation of the data and biomarker analysis in the clinic, we believe that there is ample room for other targets where Syk leads. Any delay or restricted label for tofacitinib should widen the window of opportunity for fostamatinib. For full analysis of the Syk target and RIGL, please read our report, released on June 18, 2012 and titled, “RIGEL - Oral RA Market - Room for Syk Also.
COMPANIES MENTIONED
RIGEL
RIGEL
